Publication: 3495

Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance)
      QxMD      Google Scholar   
Citation:
Angiogenesis vol 25 (1) 47-55
Year:
2022
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Meta-Analysis
Data Sharing:
Alliance-data-source,-external-user
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
11
Parents:
None
Children:
None
Program:
TRP
Primary Committee:
Correl Sci NOS
Sec. Committees:
   
Pharmas:
Abraxis BioScience, Bristol Meyers Squibb, Celgene, Genentech  
Grants:
U10CA180821, U10CA180882, U24CA196171, UG1CA233253, UG1CA233327, UG1CA233337, UG1CA233373  
Corr. Author:
 
Authors:
                 
Networks:
LAPS-IL057, LAPS-NC007, LAPS-NC010   
Study
Alliance-A152114
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-80303, CALGB-90401
Phases:
N/A, 3
Keywords:
Bevacizumab, hypertension, angiopoietin-2, VEGF-A, VCAM-1